Subscribe
shutterstock_1862407378_ralf_liebhold
Ralf Liebhold / Shutterstock.com
6 July 2021GenericsAlex Baldwin

Teva sues two Indian generics over Huntington’s treatment

Teva Pharmaceuticals has filed lawsuits  in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Generics
Generics win anti-pay-for-delay bill challenge
14 December 2021   The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Generics
Amgen, Teva to face Sensipar monopoly claims
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Generics
Generics win anti-pay-for-delay bill challenge
14 December 2021   The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Generics
Amgen, Teva to face Sensipar monopoly claims
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Generics
Generics win anti-pay-for-delay bill challenge
14 December 2021   The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Generics
Amgen, Teva to face Sensipar monopoly claims
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB